Alder Biopharmaceuticals

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles:   As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.   As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

SAN DIEGO--(BUSINESS WIRE)-- #cancer--Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance

Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance

Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy

VALBY, Denmark and BOTHELL, Wash., Oct.  11, 2019  (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (NASDAQ: ALDR) (Alder) each filed updated tender offer materials with the U.S. Securities and Exchange Commission (SEC) in connection with Lundbeck's pending tender offer (the Offer), for all outstanding shares of Alder, whereby Alder stockholders are being offered an upfront payment for USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional USD 2.00 per share upon approval of eptinezumab by the European Medicines Agency, representing a total potential consideration of USD 20.00 per share.

Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC

ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine

Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine

A Denmark-based drugmaker thought the biotech was too cheap to pass up.

Here's Why Alder Biopharmaceuticals More Than Doubled in September

American Woodmark

Columbia Sportswear Company

Dick's Sporting Goods

Leap Therapeutics

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

Use Rising P/E Strategy to Grab 5 Winning Stocks

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

A generous buyout offer has given investors something to cheer about.

Here's Why Alder Biopharmaceuticals Is Rocketing Higher Today

Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 83% in premarket trading Monday.

This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal

Merger Monday dawned with Danish pharma company Lundbeck announcing a definitive agreement to buy U.S.-based Alder Biopharmaceuticals Inc.

Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B

Shares of Alder BioPharmaceuticals Inc. ALDR, +83.90% blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S HLUYY, -0.89% LUN, -0.59% in a deal valued at $1.95 billion.

Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal

VALBY, Denmark and BOTHELL, Wash., Sept.  16, 2019  (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (NASDAQ: ALDR) (Alder) today announced a definitive agreement for Lundbeck to acquire Alder. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Alder, whereby Alder stockholders will be offered an upfront payment for USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional USD 2.00 per share upon approval of eptinezumab by the European Medicines Agency (EMA), representing a total potential consideration of USD 20.00 per share. The transaction is valued at up to USD 1.95 billion (approximately DKK 13 billion) net of cash, on a fully diluted basis.

Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash

Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its binding and selectivity to pituitary adenylate cyclase-activating peptide -

Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society

BOTHELL, Wash., Aug.  30, 2019  (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted an award of 11,500 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective August 27, 2019.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals, Inc. (ALDR) CEO Bob Azelby on Q2 2019 Results - Earnings Call Transcript

Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Buy

Alder Biopharmaceuticals, Inc. (ALDR) CEO Bob Azelby on Q1 2019 Results - Earnings Call Transcript

Alder Biopharmaceuticals could be an acquisition target, an analyst said Tuesday after the Food and Drug Administration accepted its application for a migraine-prevention treatment.

News for Alder Biopharmaceuticals Stock (ALDR)